ABILIFY MAINTENA KIT Drug Patent Profile

Which patents cover Abilify Maintena Kit, and what generic alternatives are available?

Abilify Maintena Kit is a drug marketed by Otsuka Pharm Co Ltd and is included in one NDA. There are six patents protecting this drug and one Paragraph IV challenge.

This drug has forty-four patent family members in thirty countries.

The generic ingredient in ABILIFY MAINTENA KIT is aripiprazole. There are forty-nine drug master file entries for this compound. Forty-eight suppliers are listed for this compound. Additional details are available on the aripiprazole profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Abilify Maintena Kit

A generic version of ABILIFY MAINTENA KIT was approved as aripiprazole by ALEMBIC on April 28^th, 2015.

Summary for ABILIFY MAINTENA KIT

International Patents:	44
US Patents:	6
Applicants:	1
NDAs:	1
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for ABILIFY MAINTENA KIT

Paragraph IV (Patent) Challenges for ABILIFY MAINTENA KIT

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
ABILIFY MAINTENA KIT	Extended-release Injectable Suspension	aripiprazole	300 mg/vial and 400 mg/vial	202971	1	2021-12-20

US Patents and Regulatory Information for ABILIFY MAINTENA KIT

ABILIFY MAINTENA KIT is protected by fifteen US patents.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Otsuka Pharm Co Ltd	ABILIFY MAINTENA KIT	aripiprazole	FOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR	202971-004	Sep 29, 2014		RX	Yes	Yes	11,344,547
Otsuka Pharm Co Ltd	ABILIFY MAINTENA KIT	aripiprazole	FOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR	202971-004	Sep 29, 2014		RX	Yes	Yes	11,648,347		Y
Otsuka Pharm Co Ltd	ABILIFY MAINTENA KIT	aripiprazole	FOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR	202971-002	Feb 28, 2013		RX	Yes	Yes	11,648,347		Y
Otsuka Pharm Co Ltd	ABILIFY MAINTENA KIT	aripiprazole	FOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR	202971-004	Sep 29, 2014		RX	Yes	Yes	11,400,087
Otsuka Pharm Co Ltd	ABILIFY MAINTENA KIT	aripiprazole	FOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR	202971-004	Sep 29, 2014		RX	Yes	Yes	10,980,803

International Patents for ABILIFY MAINTENA KIT

See the table below for patents covering ABILIFY MAINTENA KIT around the world.

Country	Patent Number	Title	Estimated Expiration
Canada	2543242	FORMULATION D'ARIPIPRAZOLE INJECTABLE STERILE A LIBERATION CONTROLEE ET PROCEDE (CONTROLLED RELEASE STERILE INJECTABLE ARIPIPRAZOLE FORMULATION AND METHOD)
Ukraine	84924	КРИСТАЛЛИЧЕСКИЙ БЕЗВОДНЫЙ АРИПИПРАЗОЛ F, СПОСОБ ЕГО ПОЛУЧЕНИЯ, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, СОДЕРЖАЩАЯ АРИПИПРАЗОЛ F, И СПОСОБ ЕЕ ПОЛУЧЕНИЯ;АРИПІПРАЗОЛ F, СПОСІБ ЙОГО ОДЕРЖАННЯ, ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ, ЩО МІСТИТЬ АРИПІПРАЗОЛ F, ТА СПОСІБ ЇЇ ОДЕРЖАННЯ (CRYSTAL ANHYDROUS ARYPIPRASOLE F, A METHOD FOR ITS OBTAINING, PHARMACEUTICAL COMPOSITIONS, CONTAINING ARYPIPRASOLE F, AND METHOD FOR ITS OBTAINING)
South Korea	101962085
Argentina	073111	LA PREPARACION ORAL SOLIDA FARMACEUTICA CONTENIENDO CRISTALES DE ARIPIPRAZOL DE BAJA HIGROSCOPICIDAD Y PROCESO PARA LA PREPARACION DE LA MISMA
Canada	2688915	SUBSTANCE PHARMACEUTIQUE D'ARIPIPRAZOLE FAIBLEMENT HYGROSCOPIQUE ET METHODES DE PREPARATION ASSOCIEES (LOW HYGROSCOPIC ARIPIPRAZOLE DRUG SUBSTANCE AND PROCESSES FOR THE PREPARATION THEREOF)

Supplementary Protection Certificates for ABILIFY MAINTENA KIT

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1675573	92427	Luxembourg		PRODUCT NAME: ARIPIPRAZOLE
1675573	C01675573/01	Switzerland		PRODUCT NAME: ARIPIPRAZOL; REGISTRATION NO/DATE: SWISSMEDIC 63177 28.04.2014
1675573	239 5013-2014	Slovakia		PRODUCT NAME: ARIPIPRAZOL; REGISTRATION NO/DATE: EU/1/13/882/001 - EU/1/13/882/004 20131119
1675573	32/2014	Austria		PRODUCT NAME: ARIPIPRAZOL; REGISTRATION NO/DATE: EU/1/13/882 (MITTEILUNG) 20131119
1675573	C300669	Netherlands		PRODUCT NAME: ARIPIPRAZOLE; REGISTRATION NO/DATE: EU/1/13/882 20131115

ABILIFY MAINTENA KIT Market Analysis and Financial Projection

Last updated: April 26, 2026

Investment scenario and fundamentals analysis for ABILIFY MAINTENA KIT

ABILIFY MAINTENA KIT is the marketed branded long-acting injectable (LAI) antipsychotic containing aripiprazole in a monthly depot format. The investment profile is driven by (1) the durability of aripiprazole LAI demand versus oral competition, (2) payer and formulary access, (3) dosing and administration economics relative to alternative LAIs, and (4) patent and exclusivity timing across key markets. This analysis outlines the investability drivers, operating fundamentals, and risk factors that typically determine near-to-mid cycle outcomes for an LAI franchise.

---

What is ABILIFY MAINTENA KIT and how is it positioned commercially?

Product identity

• Name: ABILIFY MAINTENA KIT
• Active ingredient: aripiprazole
• Dosage form: Long-acting injectable (LAI) depot for monthly administration (IM)
• Therapeutic area: Psychiatry, antipsychotic treatment

Commercial positioning

• LAI antipsychotics compete on adherence outcomes, relapse reduction, and clinician and payer preference for depot formulations over oral maintenance in certain subpopulations.
• ABILIFY MAINTENA competes against other monthly LAIs and, indirectly, oral aripiprazole and other antipsychotic maintenance options.

Core demand model

• Demand is pulled by the diagnosed population eligible for LAI maintenance and by conversion from oral to depot.
• Retention depends on switching dynamics among LAIs and on tolerance and tolerability in real-world practice.

---

What are the key investment fundamentals for an aripiprazole LAI franchise?

1) Pricing, access, and net revenue resilience

For a branded LAI, net revenue is typically governed by:

• Wholesale acquisition cost (WAC) vs rebates: rebate intensity reflects payer consolidation, managed care contracting, and specialty pharmacy dynamics.
• Formulary placement: prior authorization and step therapy determine uptake and persistence.
• Conversion costs: onboarding and administration workflows influence clinician uptake; payer coverage influences conversion rate from oral.

Investment implication

• When formulary status is stable and dosing is “sticky,” revenue tends to track patient retention more than new patient starts.

2) Uptake dynamics and share within the LAI segment

LAI share is shaped by:

• Clinician familiarity and administration training
• Patient and caregiver preference for monthly dosing (vs biweekly or other schedules)
• Switching behavior within the LAI market when tolerability or coverage changes

Investment implication

• The franchise value is often less about broad market growth and more about maintaining share in the LAI maintenance slice.

3) Manufacturing, supply chain, and execution

LAIs impose operational constraints:

• Sterile manufacturing capacity and batch release cadence
• Cold chain or storage handling requirements
• Distribution planning to avoid backorders that interrupt continuity of dosing

Investment implication

• Operational reliability protects retention and prevents payer “re-boarding” friction.

4) Label breadth and guideline-aligned use

Sales durability often correlates with:

• Label breadth for maintenance and relapse prevention
• Guideline acceptance for long-term schizophrenia management
• Use patterns that match dosing schedules and clinical pathways

Investment implication

• Stable label scope supports forecast confidence; label constraints raise downside risk.

---

What are the competitive drivers and substitute threats?

Direct LAI competition

ABILIFY MAINTENA faces competition from:

• Other monthly LAI antipsychotics
• Other maintenance depots with different dosing intervals and initiation requirements

Key competitive variables

• Total payer cost of therapy (drug + administration + monitoring)
• Demonstrated tolerability in target populations
• Coverage rules that determine whether a plan prefers one depot over another

Oral substitute pressure

Oral aripiprazole and other antipsychotics are substitutes through:

• Lower administration burden
• Potentially lower total cost where injectables face restrictive policies

Investment implication

• Oral substitution pressure typically rises when LAI coverage narrows or when payer tools push managed switching.

---

How should investors frame the market size and demand quality for ABILIFY MAINTENA?

Demand is “adherence-based,” not purely incidence-based.

• LAI growth depends on conversion and retention, not just diagnosed prevalence.
• The highest-quality demand comes from patients maintained long-term due to relapse risk, adherence failure, or clinician/payer prioritization of depot therapy.

Metric that matters in diligence

• Persistence and treatment duration: longer persistence smooths quarterly volatility.
• Switch rate within LAIs: high switching erodes the assumption of stable revenue.

---

What is the patent and exclusivity risk profile for ABILIFY MAINTENA?

Patent and exclusivity diligence lens (investment-grade)

• Composition-of-matter (CoM) and process patents: determine generic entry risk.
• Formulation and delivery-device related patents: can extend exclusivity on specific depot technologies.
• Regulatory exclusivities: market protection can vary by jurisdiction.

Practical risk

• Any erosion in patent barriers increases probability of generic LAI competition, which is typically high impact given branded pricing and payer tendering dynamics in specialty markets.

---

What would an investment scenario look like under three operating paths?

Base case (steady-state retention, moderate pricing pressure)

Assumptions commonly used:

• Stable formulary positioning
• Limited supply disruptions
• Competition shifts gradually rather than abruptly
• Net price declines moderate due to routine rebate pressure

Expected outcome

• Revenue growth tracks low single to mid single digits driven by patient retention and incremental share.
• Profitability remains supported by scale manufacturing and continued payer access.

Bull case (share gains in LAI conversion and favorable contracting)

Assumptions:

• Higher conversion from oral in target plans
• Improved payer placement based on health plan outcomes
• Competitive advantage persists on tolerability and dosing management

Expected outcome

• Share expansion in monthly LAI maintenance.
• Net revenue outperforms market growth; margin holds or improves with scale and favorable rebates.

Bear case (coverage tightening or competitive switching accelerates)

Assumptions:

• Payer step edits restrict access to premium depot options
• Increased switching to a competing depot due to net cost or clinical preference
• Supply issues or batch variability interrupt treatment continuity

Expected outcome

• Revenue decline driven by reduced starts and higher churn rather than pure incidence fall.
• Margin compresses as rebates rise and volume shifts to lower-margin channels.

---

Key business model drivers to evaluate in diligence (what moves returns)

1) Contracting and rebate trajectory

• Evidence that net price erosion is controlled supports valuation stability.
• Evidence of intensifying rebate pressure typically signals competitive pricing and plan leverage.

2) Channel mix (institutional vs specialty pharmacy)

• LAIs often distribute through specialty channels tied to payer authorization.
• Mix changes can affect speed-to-ship and returns on inventory.

3) Persistence and dose adherence

• LAI franchise economics are more sensitive to dosing continuity than to new patient starts.
• Persistence trends can be inferred from prescription pattern data if available in internal or paid data sources.

4) Manufacturing execution and lot supply

• Any pattern of delays or backorders can directly impair treatment continuity and lead to switching.

---

What underwriting KPIs best map to ABILIFY MAINTENA performance?

KPI	What it tells you	Why it matters for LAIs
Net revenue per treated patient	Effective pricing and rebate outcome	LAIs are retention-driven; pricing sets profit more than volume
Treated patient count trend	Demand strength and conversion	Counts reflect both starts and persistence
Switch rate (LAI-to-LAI)	Competitive switching intensity	High switching undermines franchise durability
Authorization approval rate and cycle time	Access friction	Step edits and PA delays suppress starts and disrupt continuity
Backorder rate / supply fill rate	Execution risk	Missed dosing leads to relapse and payer relisting friction

---

Key Takeaways

• ABILIFY MAINTENA KIT is an aripiprazole monthly LAI, and its investment case depends primarily on payer access, retention, and competitive switching rather than incidence growth alone.
• The most material upside comes from share gains in LAI conversion and favorable contracting; the most material downside comes from coverage tightening and accelerated switching to other depots or oral alternatives.
• Underwriting should anchor on net revenue per treated patient, persistence, authorization friction, and supply execution, with patent/exclusivity timelines treated as a top-tier risk variable.

---

FAQs

1) What fundamentally drives revenue for ABILIFY MAINTENA?

Revenue is driven by treated patient persistence (monthly dosing continuity) and payer-driven access that governs starts, retention, and switching.

2) How do LAI competitors typically affect ABILIFY MAINTENA?

Competitors affect outcomes through net price contracting, formulary positioning, and real-world switching, often more than through clinical differentiation alone.

3) What diligence indicators signal risk to persistence?

Rising switch rates, increased authorization friction, and any supply-related treatment interruptions are direct indicators of persistence risk.

4) What is the role of oral aripiprazole as a substitute threat?

Oral therapy substitutes when payers use step edits or when total cost favors oral options; it can cap starts and conversion to LAIs.

5) What patent-related events matter most for investment planning?

The practical focus is on market protection windows by jurisdiction for the LAI product and the likelihood and timing of generic entry based on CoM, formulation/process, and regulatory exclusivity.

---

References

[1] U.S. Food and Drug Administration. “Drug Approval Package: ABILIFY MAINTENA (aripiprazole).” FDA.
[2] European Medicines Agency. “Abilify Maintena: EPAR - Product Information.” EMA.